INmune Bio Inc. (NASDAQ: INMB) has released its financial results for the year ended December 31, 2024. The company reported significant progress across its three platform technologies:
For its DN-TNF Platform, the company completed enrollment of 208 patients in its Phase 2 AD02 trial for Early Alzheimer's Disease, with topline results expected in June 2025. The trial demonstrated strong performance of its EMACC cognitive measure tool.
The CORDStrom Platform showed positive results in treating Recessive Dystrophic Epidermolysis Bullosa (RDEB), receiving both Rare Pediatric Disease and Orphan Drug Designations from the FDA. The company plans to file a BLA in 2025 or early 2026.
The INKmune Platform demonstrated safety and increased NK-Cell activity in its Phase I/II trial for metastatic Castration-Resistant Prostate Cancer.
Financially, the company reported a net loss of $42.1 million for 2024, with R&D expenses of $33.2 million. The company raised approximately $27.5 million through securities purchase agreements and had cash and cash equivalents of $20.9 million as of December 31, 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.